Skip to main content
. 2023 Mar 14;100(11):522–528. doi: 10.1212/WNL.0000000000201654

Figure 2. Distribution of Patients With SMA I Among Available Treatments.

Figure 2

Colour key: Blue = Switched from nusinersen to risdiplam/onasemnogene abeparvovec, Orange = Switched from risdiplam to nusinersen/onasemnogene abeparvovec, Green = Switched from onasemnogene abeparvovec to risdiplam/nusinersen, Gray = Remained on the same treatment, no switch was recorded.